$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000165495419012751 Filed on November 12, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$40.00K	$38.00K	$40.00K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.060M	$2.910M	$1.910M
YoY Change	269.63%	200.0%	-62.4%
% of Gross Profit
Research & Development	$30.94M	$57.99M	$52.28M
YoY Change	-40.82%	73.62%	101.08%
% of Gross Profit
Depreciation & Amortization	$30.00K	$20.00K	$30.00K
YoY Change	0.0%	0.0%	50.0%
% of Gross Profit
Operating Expenses	$38.00M	$60.90M	$54.19M
YoY Change	-29.88%	77.21%	74.41%
Operating Profit		-$60.86M
YoY Change		77.29%
Interest Expense	-$1.900M	$1.537M	$270.0K
YoY Change	-803.7%	595.48%	125.0%
% of Operating Profit
Other Income/Expense, Net	$290.0K	-$1.069M	$20.00K
YoY Change	1350.0%	183.55%	-60.0%
Pretax Income	-$39.57M	-$61.93M	-$53.86M
YoY Change	-26.53%	82.42%	74.53%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$39.57M	-$61.93M	-$53.86M
YoY Change	-26.53%	82.41%	74.53%
Net Earnings / Revenue	-98927.5%	-162973.68%	-134650.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$413.3K	-$690.6K	-$684.6K
COMMON SHARES
Basic Shares Outstanding	99.56M shares	94.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$140.4M	$72.50M	$68.80M
YoY Change	104.07%	-25.79%	-18.77%
Cash & Equivalents	$112.6M	$44.68M	$41.96M
Short-Term Investments	$27.80M	$27.80M	$26.80M
Other Short-Term Assets	$611.0K	$864.0K	$439.0K
YoY Change	39.18%	-92.74%	-94.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$149.2M	$80.36M	$79.03M
YoY Change	88.72%	-26.75%	-15.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$282.0K	$275.0K	$251.0K
YoY Change	12.35%	-89.42%	-90.7%
Goodwill	$799.0K	$799.0K	$799.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.300M	$1.200M	$1.200M
YoY Change	8.33%	0.0%	100.0%
Total Long-Term Assets	$13.86M	$12.97M	$4.585M
YoY Change	202.36%	176.0%	11.83%
TOTAL ASSETS
Total Short-Term Assets	$149.2M	$80.36M	$79.03M
Total Long-Term Assets	$13.86M	$12.97M	$4.585M
Total Assets	$163.0M	$93.33M	$83.62M
YoY Change	94.96%	-18.42%	-14.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$30.00M	$31.80M	$36.40M
YoY Change	-17.58%	-16.09%	40.54%
Accrued Expenses	$5.400M	$4.400M	$2.300M
YoY Change	134.78%	109.52%	27.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%	0.0%
Total Short-Term Liabilities	$84.45M	$80.20M	$38.85M
YoY Change	117.35%	99.5%	38.76%
LONG-TERM LIABILITIES
Long-Term Debt	$28.97M	$28.74M	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$18.35M
YoY Change	-100.0%	-100.0%	664.58%
Total Long-Term Liabilities	$28.97M	$28.74M	$18.35M
YoY Change	57.87%	1097.54%	664.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$84.45M	$80.20M	$38.85M
Total Long-Term Liabilities	$28.97M	$28.74M	$18.35M
Total Liabilities	$124.4M	$119.1M	$59.58M
YoY Change	108.79%	179.62%	95.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$701.2M	-$661.6M	-$528.3M
YoY Change	32.72%
Common Stock	$109.0K	$97.00K	$84.00K
YoY Change	29.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$234.0K	$234.0K	$234.0K
YoY Change	0.0%
Treasury Stock Shares	$41.31K	41.31K shares	$41.31K
Shareholders Equity	$38.60M	-$25.80M	$24.00M
YoY Change
Total Liabilities & Shareholders Equity	$163.0M	$93.33M	$83.62M
YoY Change	94.96%	-18.42%	-14.15%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$39.57M	-$61.93M	-$53.86M
YoY Change	-26.53%	82.41%	74.53%
Depreciation, Depletion And Amortization	$30.00K	$20.00K	$30.00K
YoY Change	0.0%	0.0%	50.0%
Cash From Operating Activities	-$30.40M	-$33.20M	-$33.69M
YoY Change	-9.77%	0.58%	54.19%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$70.00K	-$10.00K
YoY Change	200.0%	250.0%
Acquisitions
YoY Change
Other Investing Activities	$40.00K	$20.00K	$240.0K
YoY Change	-83.33%	-100.31%	-100.86%
Cash From Investing Activities	$0.00	-$40.00K	$240.0K
YoY Change	-100.0%	-99.38%	-100.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$50.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	98.35M	20.70M	4.690M
YoY Change	1997.01%	360.0%	-68.18%
NET CHANGE
Cash From Operating Activities	-30.40M	-33.20M	-33.69M
Cash From Investing Activities	0.000	-40.00K	240.0K
Cash From Financing Activities	98.35M	20.70M	4.690M
Net Change In Cash	67.95M	-12.54M	-28.76M
YoY Change	-336.27%	-64.12%	-18.11%
FREE CASH FLOW
Cash From Operating Activities	-$30.40M	-$33.20M	-$33.69M
Capital Expenditures	-$30.00K	-$70.00K	-$10.00K
Free Cash Flow	-$30.37M	-$33.13M	-$33.68M
YoY Change	-9.83%	0.42%	54.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	-51000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	539000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001001316
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309	shares
CY2019Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	41309	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8060758	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8060758	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5230922	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5230922	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30929
	dei	Entity Registrant Name EntityRegistrantName	TG THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Gansevoort Street, 9th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10014
	dei	City Area Code CityAreaCode	212
	dei	Local Phone Number LocalPhoneNumber	554-4484
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	TGTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99561434	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44675000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41958000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	27776000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	26943000	USD
CY2019Q3	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	7040000	USD
CY2018Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	9691000	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	864000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	439000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18350000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	119118000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	80355000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	79031000	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1248000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1241000	USD
CY2019Q3	tgtx	Leasehold Interest LeaseholdInterest	2157000	USD
CY2018Q4	tgtx	Leasehold Interest LeaseholdInterest	2294000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	275000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	251000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8493000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Goodwill Goodwill	799000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	799000	USD
CY2019Q3	us-gaap	Assets Assets	93327000	USD
CY2018Q4	us-gaap	Assets Assets	83616000	USD
CY2019Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	31780000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36377000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	44035000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	219000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1365000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	3017000	USD
CY2018Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2258000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	80197000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38854000	USD
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1462000	USD
CY2019Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	800000	USD
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	914000	USD
CY2019Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28741000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9380000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2019Q3	us-gaap	Treasury Stock Value TreasuryStockValue	234000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	59580000	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96670197	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83911855	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96628888	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83870546	shares
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	97000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	84000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	635989000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	552531000	USD
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	234000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-661643000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528345000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-25791000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24036000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93327000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83616000	USD
CY2019Q3	us-gaap	Revenues Revenues	38000	USD
CY2018Q3	us-gaap	Revenues Revenues	38000	USD
	us-gaap	Revenues Revenues	114000	USD
	us-gaap	Revenues Revenues	114000	USD
CY2019Q3	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	0	USD
CY2018Q3	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	0	USD
	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	100000	USD
	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	4000000	USD
CY2019Q3	tgtx	Non Cash Compensation Research And Development NonCashCompensationResearchAndDevelopment	1482000	USD
CY2018Q3	tgtx	Non Cash Compensation Research And Development NonCashCompensationResearchAndDevelopment	644000	USD
	tgtx	Non Cash Compensation Research And Development NonCashCompensationResearchAndDevelopment	4323000	USD
	tgtx	Non Cash Compensation Research And Development NonCashCompensationResearchAndDevelopment	4391000	USD
CY2019Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	56503000	USD
CY2018Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	32754000	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	118814000	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	98724000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57985000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33398000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	123237000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107115000	USD
CY2019Q3	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	593000	USD
CY2018Q3	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	-817000	USD
	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	1391000	USD
	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	7037000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	78221069	shares
CY2018Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1785000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	6580000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	6212000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2914000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	968000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85911878	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	74399243	shares
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66993000	USD
CY2018Q1	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	900000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7971000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13249000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	60899000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	34366000	USD
	us-gaap	Operating Expenses OperatingExpenses	131208000	USD
	us-gaap	Operating Expenses OperatingExpenses	120364000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-60861000	USD
CY2018Q1	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	52430000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7337000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-41529000	USD
CY2019Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2321000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-34328000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-131094000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-120250000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	1537000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	221000	USD
	us-gaap	Interest Expense InterestExpense	3388000	USD
	us-gaap	Interest Expense InterestExpense	657000	USD
CY2019Q3	us-gaap	Other Income OtherIncome	468000	USD
CY2018Q3	us-gaap	Other Income OtherIncome	598000	USD
	us-gaap	Other Income OtherIncome	1183000	USD
	us-gaap	Other Income OtherIncome	1285000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1069000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-377000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2205000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-628000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-61930000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-33951000	USD
	us-gaap	Profit Loss ProfitLoss	-133299000	USD
	us-gaap	Profit Loss ProfitLoss	-119622000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.61
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89667979	shares
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85232000	USD
CY2018Q2	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	1000000	USD
CY2018Q2	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	52022000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4264000	USD
CY2018Q2	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	4000000	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-44142000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101376000	USD
CY2018Q3	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	100000	USD
CY2018Q3	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	4492000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-173000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-33951000	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71744000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24036000	USD
CY2019Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	993000	USD
CY2019Q1	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	200000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27499000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1882000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-35156000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19254000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	11000	USD
CY2019Q2	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	500000	USD
CY2019Q2	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	28395000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1757000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-36212000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13205000	USD
CY2019Q3	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	400000	USD
CY2019Q3	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	20759000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2075000	USD
CY2019Q3	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	100000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-61930000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-25791000	USD
	us-gaap	Profit Loss ProfitLoss	-133299000	USD
	us-gaap	Profit Loss ProfitLoss	-119622000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5714000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11428000	USD
	tgtx	Noncash Licensing Expense NoncashLicensingExpense	100000	USD
	tgtx	Noncash Licensing Expense NoncashLicensingExpense	4000000	USD
	us-gaap	Depreciation Depreciation	72000	USD
	us-gaap	Depreciation Depreciation	64000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	-209000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Lease Incentives AmortizationOfLeaseIncentives	137000	USD
	us-gaap	Amortization Of Lease Incentives AmortizationOfLeaseIncentives	98000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1921000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	28000	USD
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-37000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2226000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-3421000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	28000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3837000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	12321000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1129000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	787000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	24651000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
	tgtx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
	tgtx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	71000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-114000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-114000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-102413000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-95235000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	97000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	23125000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	24574000	USD
	tgtx	Proceeds From Maturities ProceedsFromMaturities	22500000	USD
	tgtx	Proceeds From Maturities ProceedsFromMaturities	25600000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-722000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	942000	USD
	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	76664000	USD
	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	108945000	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	29675000	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	480000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	105859000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	108945000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2724000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14652000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43199000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57305000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45923000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44675000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71957000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70718000	USD
CY2019Q3	us-gaap	Restricted Cash RestrictedCash	1248000	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	1239000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45923000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71957000	USD
	tgtx	Accrued Financing Costs AccruedFinancingCosts	988000	USD
	tgtx	Accrued Financing Costs AccruedFinancingCosts	0	USD
	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	993000	USD
	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	0	USD
	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	100000	USD
	tgtx	Shares Issued In Connection With In Licensing Agreements SharesIssuedInConnectionWithInLicensingAgreements	0	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt;"> <b> <i>Use of Estimates </i> </b> </p> <p style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font: 10pt 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt; margin: 0pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt 'Times New Roman', Times, serif; text-align: justify; margin: 0pt;"> <b> <i>Credit Risk </i> </b> </p> <p style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font: 10pt 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt; margin: 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2019Q3	us-gaap	Cash Cash	42302000	USD
CY2018Q4	us-gaap	Cash Cash	39268000	USD
CY2019Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2373000	USD
CY2018Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2690000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44675000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41958000	USD
CY2019Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	27776000	USD
	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	35000	USD
	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	3000	USD
CY2019Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	27808000	USD
CY2018Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	26943000	USD
CY2018	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	2000	USD
CY2018	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	10000	USD
CY2018Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	26935000	USD
	tgtx	Cumulative Liability Of Note CumulativeLiabilityOfNote	19100000	USD
CY2018	tgtx	Cumulative Liability Of Note CumulativeLiabilityOfNote	18400000	USD
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8060758	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5230922	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	740000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.90
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y9M
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2019Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	95000	USD
CY2019Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	95000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	67000	USD
CY2018Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	67000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	67000	USD
	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	690000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-662000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	95000	USD
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2539540	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1916900	shares
CY2019Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2019Q3	us-gaap	Notes Payable NotesPayable	95000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	67000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	117360	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2539540	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.63
	tgtx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P9Y1M20D
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1849055000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2539540	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.63
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y1M20D
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1849055000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.7299	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	2.9161	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.8699	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	3.0577	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0196	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0249	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0256	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0272	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5300000	USD
CY2019Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	1253000	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	3381000	USD
CY2019Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	822000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2333000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2075000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5714000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	147058	shares
	tgtx	Warrants Weighted Average Exercise Price Issued WarrantsWeightedAverageExercisePriceIssued	4.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	0	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	147058	shares
	tgtx	Warrants Weighted Average Exercise Price Outstanding WarrantsWeightedAverageExercisePriceOutstanding	4.08
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	224999000	USD
CY2019Q3	us-gaap	Notes Payable Current NotesPayableCurrent	95000	USD
CY2019Q3	tgtx	Agreement Costs Current Liabilities AgreementCostsCurrentLiabilities	43000000.0	USD
CY2018Q4	us-gaap	Notes Payable NotesPayable	67000	USD
	tgtx	Cumulative Liability Of Note CumulativeLiabilityOfNote	19100000	USD
CY2018	tgtx	Cumulative Liability Of Note CumulativeLiabilityOfNote	18400000	USD
CY2018Q4	tgtx	Agreement Costs Non Current Liabilities AgreementCostsNonCurrentLiabilities	18400000	USD
CY2019Q3	tgtx	End Of Term Fee EndOfTermFee	975000	USD
CY2019Q3	tgtx	Long Term Debt Gross LongTermDebtGross	30975000	USD
CY2019Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	-2234000	USD
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	28741000	USD
	tgtx	Interest Expense Recongized As Administrative Fees InterestExpenseRecongizedAsAdministrativeFees	500000	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.08
CY2019Q3	tgtx	Class Of Warrant Or Right Fair Value ClassOfWarrantOrRightFairValue	1000000.0	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	2800000	USD
CY2019Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	200000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	500000	USD
CY2019Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	30000000	USD
CY2019Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28741000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1065000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2058000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	1065000	USD
	us-gaap	Lease Cost LeaseCost	2058000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1365000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9380000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10745000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	393000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	1551000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	1560000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	1586000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	1581000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	12061000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18732000	USD
CY2019Q3	tgtx	Operating Lease Liability Imputed Interest OperatingLeaseLiabilityImputedInterest	-7987000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10745000	USD
	tgtx	Upfront Fee Received From Sub License UpfrontFeeReceivedFromSubLicense	100000	USD
CY2018Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	100000	USD

Files In Submission

Name	View Source	Status
0001654954-19-012751-index-headers.html	Edgar Link	pending
0001654954-19-012751-index.html	Edgar Link	pending
0001654954-19-012751.txt	Edgar Link	pending
0001654954-19-012751-xbrl.zip	Edgar Link	pending
exhibit31-1.htm	Edgar Link	pending
exhibit31-2.htm	Edgar Link	pending
exhibit32-1.htm	Edgar Link	pending
exhibit32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20190930.htm	Edgar Link	pending
tgtx-20190930.xsd	Edgar Link	pending
tgtx-20190930_cal.xml	Edgar Link	unprocessable
tgtx-20190930_def.xml	Edgar Link	unprocessable
tgtx-20190930_htm.xml	Edgar Link	completed
tgtx-20190930_lab.xml	Edgar Link	unprocessable
tgtx-20190930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2019 Q4 Form 10-Q Financial Statement

#000165495419012751 Filed on November 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2019 Q4 Form 10-Q Financial Statement

#000165495419012751 Filed on November 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx